SCHEMBL7130245

SCHEMBL7130245

Cc1cc2cc(Nc3ccnc4cc(-c5c(O)nc(C(C)(C)O)n5C)sc34)ccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.55
FLT1 P17948 16/20 0.55
KDR P35968 2/20 0.46
SYK P43405 2/20 0.35
LCK P06239 1/20 0.34
YES1 P07947 1/20 0.34
LYN P07948 1/20 0.34
HCK P08631 1/20 0.34
FGR P09769 1/20 0.34
SRC P12931 1/20 0.34
EPHA3 P29320 1/20 0.34
FLT3 P36888 1/20 0.34
BTK Q06187 1/20 0.34
DDR1 Q08345 1/20 0.34
DDR2 Q16832 1/20 0.34
PRKCQ Q04759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118437 0.86 EGFR (0.55) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7120873 0.81 EGFR (0.57) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7676008 0.80 EGFR (0.56) EGFRFLT1KDRSYKLCK
SCHEMBL7121125 0.79 EGFR (0.57) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7665955 0.79 EGFR (0.57) EGFRFLT1KDRSYK
SCHEMBL7664845 0.79 EGFR (0.57) EGFRFLT1KDRSYK
SCHEMBL7124553 0.79 EGFR (0.61) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7119371 0.78 EGFR (0.59) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7124425 0.78 EGFR (0.66) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7124392 0.77 EGFR (0.63) EGFRFLT1KDRSYKPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 EGFR 2961/4885FLT1 1043/4885KDR 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.